首页> 美国卫生研究院文献>Mediators of Inflammation >Nuclear Receptors in the Pathogenesis and Management of Inflammatory Bowel Disease
【2h】

Nuclear Receptors in the Pathogenesis and Management of Inflammatory Bowel Disease

机译:核受体在炎症性肠病的发病机理和治疗中的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nuclear receptors (NRs) are ligand-dependent transcription factors that regulate the transcription of target genes. Previous epidemiological and genetic studies have documented the association of NRs with the risk of inflammatory bowel disease (IBD). Although the mechanisms of action of NRs in IBD have not been fully established, accumulating evidence has demonstrated that NRs play complicated roles in regulating intestinal immunity, mucosal barriers, and intestinal flora. As one of the first-line medications for the treatment of IBD, 5-aminosalicylic acid (5-ASA) activates peroxisome proliferator-activated receptor gamma (PPARγ) to attenuate colitis. The protective roles of rifaximin and rifampicin partly depend on promoting pregnane X receptor (PXR) expression. The aims of this review are to discuss the roles of several important NRs, such as PPARγ, PXR, vitamin D receptor (VDR), farnesoid X receptor (FXR), and RAR-related orphan receptor gammat (RORγt), in the pathogenesis of IBD and management strategies based on targeting these receptors.
机译:核受体(NRs)是依赖配体的转录因子,可调节靶基因的转录。先前的流行病学和遗传研究已记录了NR与炎症性肠病(IBD)风险的关系。尽管尚未完全确定NRs在IBD中的作用机制,但越来越多的证据表明NRs在调节肠道免疫,粘膜屏障和肠道菌群中起着复杂的作用。作为治疗IBD的一线药物,5-氨基水杨酸(5-ASA)激活过氧化物酶体增殖物激活受体γ(PPARγ)来减轻结肠炎。利福昔明和利福平的保护作用部分取决于促进孕烷X受体(PXR)的表达。这篇综述的目的是讨论几种重要的NRs,如PPARγ,PXR,维生素D受体(VDR),法呢素X受体(FXR)和RAR相关的孤儿受体gammat(RORγt)在发病中的作用。针对这些受体的IBD和管理策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号